Which has higher earnings & valuation, CCCC or XNCR?

Xencor has higher revenue and earnings than C4 Therapeutics. Xencor is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio C4 Therapeutics $35.95M 14.51 -$104.99M -$1.19 N/A Xencor $125.58M 13.82 -$91.92M -$2.17 N/A

Is CCCC or XNCR more profitable?

Xencor has a net margin of -155.59% compared to C4 Therapeutics' net margin of -289.44%. Xencor's return on equity of -28.66% beat C4 Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets C4 Therapeutics -289.44% -47.15% -31.91% Xencor -155.59% -28.66% -20.38%

Does the media refer more to CCCC or XNCR?

In the previous week, C4 Therapeutics had 6 more articles in the media than Xencor. MarketBeat recorded 14 mentions for C4 Therapeutics and 8 mentions for Xencor. C4 Therapeutics' average media sentiment score of 0.59 beat Xencor's score of 0.41 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Xencor 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TYRA or CCCC?

In the previous week, C4 Therapeutics had 11 more articles in the media than Tyra Biosciences. MarketBeat recorded 14 mentions for C4 Therapeutics and 3 mentions for Tyra Biosciences. C4 Therapeutics' average media sentiment score of 0.59 beat Tyra Biosciences' score of -0.38 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor CCCC or VIR?

In the previous week, Vir Biotechnology had 6 more articles in the media than C4 Therapeutics. MarketBeat recorded 20 mentions for Vir Biotechnology and 14 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.59 beat Vir Biotechnology's score of -0.12 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CCCC or MAZE?

In the previous week, Maze Therapeutics had 8 more articles in the media than C4 Therapeutics. MarketBeat recorded 22 mentions for Maze Therapeutics and 14 mentions for C4 Therapeutics. Maze Therapeutics' average media sentiment score of 0.69 beat C4 Therapeutics' score of 0.59 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Maze Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVBP or CCCC?

In the previous week, C4 Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 14 mentions for C4 Therapeutics and 12 mentions for ArriVent BioPharma. C4 Therapeutics' average media sentiment score of 0.59 beat ArriVent BioPharma's score of 0.24 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral C4 Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

C4 Therapeutics (CCCC) Competitors

$4.24 +0.16 (+3.92%)

Closing price 04:00 PM Eastern

Extended Trading

$4.22 -0.02 (-0.45%)

As of 05:55 PM Eastern

Compare

CCCC vs. XNCR, TYRA, VIR, MAZE, and AVBP

Should you buy C4 Therapeutics stock or one of its competitors? C4 Therapeutics's main competitors and comparable companies include Xencor (XNCR), Tyra Biosciences (TYRA), Vir Biotechnology (VIR), Maze Therapeutics (MAZE), and ArriVent BioPharma (AVBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does C4 Therapeutics compare to Xencor?

C4 Therapeutics (NASDAQ:CCCC) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

C4 Therapeutics has a beta of 2.91, meaning that its share price is 191% more volatile than the broader market. Comparatively, Xencor has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Xencor has higher revenue and earnings than C4 Therapeutics. Xencor is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	14.51	-$104.99M	-$1.19	N/A
Xencor	$125.58M	13.82	-$91.92M	-$2.17	N/A

78.8% of C4 Therapeutics shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Xencor shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, C4 Therapeutics had 6 more articles in the media than Xencor. MarketBeat recorded 14 mentions for C4 Therapeutics and 8 mentions for Xencor. C4 Therapeutics' average media sentiment score of 0.59 beat Xencor's score of 0.41 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Xencor	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xencor has a net margin of -155.59% compared to C4 Therapeutics' net margin of -289.44%. Xencor's return on equity of -28.66% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-47.15%	-31.91%
Xencor	-155.59%	-28.66%	-20.38%

C4 Therapeutics currently has a consensus target price of $7.75, indicating a potential upside of 82.78%. Xencor has a consensus target price of $24.86, indicating a potential upside of 6.50%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe C4 Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

C4 Therapeutics beats Xencor on 10 of the 15 factors compared between the two stocks.

How does C4 Therapeutics compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Tyra Biosciences currently has a consensus target price of $46.90, suggesting a potential upside of 85.45%. C4 Therapeutics has a consensus target price of $7.75, suggesting a potential upside of 82.78%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Tyra Biosciences is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

C4 Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
C4 Therapeutics	$35.95M	14.51	-$104.99M	-$1.19	N/A

In the previous week, C4 Therapeutics had 11 more articles in the media than Tyra Biosciences. MarketBeat recorded 14 mentions for C4 Therapeutics and 3 mentions for Tyra Biosciences. C4 Therapeutics' average media sentiment score of 0.59 beat Tyra Biosciences' score of -0.38 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
C4 Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tyra Biosciences has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.91, meaning that its stock price is 191% more volatile than the broader market.

Tyra Biosciences has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. Tyra Biosciences' return on equity of -46.39% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
C4 Therapeutics	-289.44%	-47.15%	-31.91%

Summary

Tyra Biosciences and C4 Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Vir Biotechnology?

C4 Therapeutics (NASDAQ:CCCC) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

C4 Therapeutics has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

In the previous week, Vir Biotechnology had 6 more articles in the media than C4 Therapeutics. MarketBeat recorded 20 mentions for Vir Biotechnology and 14 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.59 beat Vir Biotechnology's score of -0.12 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

C4 Therapeutics presently has a consensus target price of $7.75, indicating a potential upside of 82.78%. Vir Biotechnology has a consensus target price of $20.63, indicating a potential upside of 123.21%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

C4 Therapeutics has a net margin of -289.44% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-47.15%	-31.91%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

C4 Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	14.51	-$104.99M	-$1.19	N/A
Vir Biotechnology	$68.56M	22.81	-$437.99M	-$1.86	N/A

Summary

Vir Biotechnology beats C4 Therapeutics on 9 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to Maze Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

C4 Therapeutics has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	14.51	-$104.99M	-$1.19	N/A
Maze Therapeutics	$167.50M	9.01	-$131.12M	-$2.53	N/A

C4 Therapeutics has a beta of 2.91, meaning that its share price is 191% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

78.8% of C4 Therapeutics shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

C4 Therapeutics currently has a consensus price target of $7.75, indicating a potential upside of 82.78%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 142.83%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Maze Therapeutics had 8 more articles in the media than C4 Therapeutics. MarketBeat recorded 22 mentions for Maze Therapeutics and 14 mentions for C4 Therapeutics. Maze Therapeutics' average media sentiment score of 0.69 beat C4 Therapeutics' score of 0.59 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Maze Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. Maze Therapeutics' return on equity of -37.24% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-47.15%	-31.91%
Maze Therapeutics	N/A	-37.24%	-32.35%

Summary

Maze Therapeutics beats C4 Therapeutics on 9 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

ArriVent BioPharma currently has a consensus price target of $44.43, suggesting a potential upside of 50.55%. C4 Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 82.78%. Given C4 Therapeutics' higher possible upside, analysts clearly believe C4 Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

C4 Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
C4 Therapeutics	$35.95M	14.51	-$104.99M	-$1.19	N/A

In the previous week, C4 Therapeutics had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 14 mentions for C4 Therapeutics and 12 mentions for ArriVent BioPharma. C4 Therapeutics' average media sentiment score of 0.59 beat ArriVent BioPharma's score of 0.24 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
C4 Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

ArriVent BioPharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.91, indicating that its share price is 191% more volatile than the broader market.

ArriVent BioPharma has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -47.15% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-52.47%	-48.68%
C4 Therapeutics	-289.44%	-47.15%	-31.91%

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

C4 Therapeutics beats ArriVent BioPharma on 11 of the 15 factors compared between the two stocks.

Get C4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CCCC vs. The Competition

Export

Metric	C4 Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$521.65M	$3.71B	$6.97B	$13.05B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-4.24	10.68	269.86	25.30
Price / Sales	14.51	1,307.84	602.27	101.40
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	1.60	17.49	13.08	6.33
Net Income	-$104.99M	-$13.32M	$3.45B	$347.70M
7 Day Performance	13.67%	1.74%	1.12%	1.07%
1 Month Performance	11.29%	1.60%	1.79%	1.03%
1 Year Performance	80.43%	56.43%	67.69%	20.77%

C4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CCCC C4 Therapeutics	1.6039 of 5 stars	$4.24 +3.9%	$7.75 +82.8%	+75.1%	$521.65M	$35.95M	N/A	150	News Coverage Earnings Report Analyst Revision
XNCR Xencor	1.4023 of 5 stars	$21.81 +1.0%	$24.86 +14.0%	+197.8%	$1.62B	$125.58M	N/A	280
TYRA Tyra Biosciences	2.5885 of 5 stars	$25.96 -1.1%	$46.90 +80.7%	+132.7%	$1.54B	N/A	N/A	20
VIR Vir Biotechnology	2.0022 of 5 stars	$8.92 +0.3%	$20.63 +131.4%	+96.9%	$1.51B	$68.56M	N/A	580	Analyst Revision
MAZE Maze Therapeutics	2.0323 of 5 stars	$27.06 -0.8%	$66.00 +143.9%	+103.5%	$1.50B	$167.50M	N/A	121	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CCCC) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

C4 Therapeutics (CCCC) Competitors

CCCC vs. XNCR, TYRA, VIR, MAZE, and AVBP

How does C4 Therapeutics compare to Xencor?

Summary

How does C4 Therapeutics compare to Tyra Biosciences?

Summary

How does C4 Therapeutics compare to Vir Biotechnology?

Summary

How does C4 Therapeutics compare to Maze Therapeutics?

Summary

How does C4 Therapeutics compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

C4 Therapeutics (CCCC) Competitors

CCCC vs. XNCR, TYRA, VIR, MAZE, and AVBP

How does C4 Therapeutics compare to Xencor?

Which has more volatility & risk, CCCC or XNCR?

Which has higher earnings & valuation, CCCC or XNCR?

Do institutionals and insiders believe in CCCC or XNCR?

Does the media refer more to CCCC or XNCR?

Is CCCC or XNCR more profitable?

Do analysts recommend CCCC or XNCR?

Summary

How does C4 Therapeutics compare to Tyra Biosciences?

Do analysts recommend TYRA or CCCC?

Which has better earnings and valuation, TYRA or CCCC?

Does the media refer more to TYRA or CCCC?

Do insiders & institutionals have more ownership in TYRA or CCCC?

Which has more volatility and risk, TYRA or CCCC?

Is TYRA or CCCC more profitable?

Summary

How does C4 Therapeutics compare to Vir Biotechnology?

Do institutionals & insiders believe in CCCC or VIR?

Which has more risk and volatility, CCCC or VIR?

Does the media favor CCCC or VIR?

Do analysts prefer CCCC or VIR?

Is CCCC or VIR more profitable?

Which has better earnings & valuation, CCCC or VIR?

Summary

How does C4 Therapeutics compare to Maze Therapeutics?

Which has better valuation and earnings, CCCC or MAZE?

Which has more risk and volatility, CCCC or MAZE?

Do institutionals and insiders believe in CCCC or MAZE?

Do analysts rate CCCC or MAZE?

Does the media favor CCCC or MAZE?

Is CCCC or MAZE more profitable?

Summary

How does C4 Therapeutics compare to ArriVent BioPharma?

Do analysts prefer AVBP or CCCC?

Which has higher earnings & valuation, AVBP or CCCC?

Does the media prefer AVBP or CCCC?

Which has more risk and volatility, AVBP or CCCC?

Is AVBP or CCCC more profitable?

Do institutionals & insiders have more ownership in AVBP or CCCC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools